TY - JOUR
T1 - Early use of chemotherapy in conjunction with radical prostatectomy
AU - Alumkal, Joshi J.
AU - Carducci, Michael A.
PY - 2004/12
Y1 - 2004/12
N2 - Since the advent of prostate-specific antigen testing, most prostate cancers are now detected in an early, organ-confined stage. Because of this, local therapies including radical prostatectomy and irradiation have become more common in the treatment of men with prostate cancer. Nonetheless, relapse of disease remains a major problem. In the past decade, many groups have studied the early use of chemotherapy with or without hormonal therapy after radical prostatectomy, specifically, and found it to be safe. In this article, we will summarize the data for neoadjuvant and adjuvant chemotherapy and chemohormonal therapy in conjunction with radical prostatectomy. We will also highlight more recent clinical trial designs, including a multicenter pilot study of adjuvant docetaxel therapy, which has several important distinctions when compared with previous studies, including the active chemotherapeutic agent docetaxel, better risk-adapted patient accrual, and higher statistical power. Although data for this study are not yet mature, these differences in clinical trial design make such studies in adjuvant chemotherapy for patients with high-risk prostate cancer novel and promising.
AB - Since the advent of prostate-specific antigen testing, most prostate cancers are now detected in an early, organ-confined stage. Because of this, local therapies including radical prostatectomy and irradiation have become more common in the treatment of men with prostate cancer. Nonetheless, relapse of disease remains a major problem. In the past decade, many groups have studied the early use of chemotherapy with or without hormonal therapy after radical prostatectomy, specifically, and found it to be safe. In this article, we will summarize the data for neoadjuvant and adjuvant chemotherapy and chemohormonal therapy in conjunction with radical prostatectomy. We will also highlight more recent clinical trial designs, including a multicenter pilot study of adjuvant docetaxel therapy, which has several important distinctions when compared with previous studies, including the active chemotherapeutic agent docetaxel, better risk-adapted patient accrual, and higher statistical power. Although data for this study are not yet mature, these differences in clinical trial design make such studies in adjuvant chemotherapy for patients with high-risk prostate cancer novel and promising.
KW - Adjuvant therapy
KW - Chemohormonal therapy
KW - Docetaxel
KW - Estramustine
KW - Localized prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=11144222571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144222571&partnerID=8YFLogxK
U2 - 10.3816/CGC.2004.n.024
DO - 10.3816/CGC.2004.n.024
M3 - Review article
C2 - 15636680
AN - SCOPUS:11144222571
SN - 1540-0352
VL - 3
SP - 144
EP - 149
JO - Clinical Prostate Cancer
JF - Clinical Prostate Cancer
IS - 3
ER -